# GIP: Glucose-dependent Insulinotropic Peptide

> **NCT00239707** · PHASE1 · COMPLETED · sponsor: **National Institute on Aging (NIA)** · enrollment: 41 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** GIP
- **DRUG:** Modified GIP
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT00239707
- **Lead sponsor:** National Institute on Aging (NIA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239707, "GIP: Glucose-dependent Insulinotropic Peptide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00239707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*